4882

Perseus Proteomics Inc.

株式会社ペルセウスプロテオミクス
Pharmaceutical
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.
← Companies
Price
¥155
Market Cap
¥2.3B
Ent. Value
—
Net Cash est
—
Shares Out.
14.7M
P / E
—
EV / EBIT
—
P / Book
1.69×
P / NCAV
1.65×
Div. Yield
—
Financials
Metric FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥120M ¥100M ¥94M ¥72M
Cost of Sales ¥16M ¥13M ¥8M ¥4M
Gross Profit ¥104M ¥88M ¥87M ¥68M
SG&A ¥930M ¥982M ¥784M ¥540M
Operating Income ¥-826M ¥-895M ¥-698M ¥-472M
Non-Operating Income ¥4M ¥21M ¥8M ¥9M
Interest Income ¥2M ¥0M ¥0M ¥0M
Non-Operating Expenses ¥7M ¥6M ¥0M ¥19M
Ordinary Income ¥-830M ¥-879M ¥-690M ¥-482M
Pre-tax Income ¥-902M ¥-1.1B ¥-785M ¥-597M
Income Taxes ¥2M ¥2M ¥2M ¥2M
Current Tax ¥2M ¥2M ¥2M ¥2M
Net Income (owners) ¥-905M ¥-1.1B ¥-787M ¥-599M
EBITDA ¥-824M ¥-891M ¥-692M ¥-469M
EPS ¥-63.41 ¥-93.69 ¥-66.93 ¥-54.47
Shares Outstanding 14.7M 11.9M 11.8M 11.8M
Shares Issued (total) 14.7M 11.9M 11.8M 11.8M